Research Article

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Claudia Fabiani,1 Jurgen Sota,2 Maite Sainz-de-la-Maza,3 Laura Pelegrín,3 Giacomo Emmi,4 Giuseppe Lopalco,5 Florenzo Iannone,5 Lorenzo Vannozzi,6 Silvana Guerrero,7 Maria Chiara Gelmi,1 Donato Rigante,8 Gian Marco Tosi,1 José Hernández-Rodríguez,9 and Luca Cantarini2

1Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
2Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease, Rheumatology Unit of the Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
3Clinical Institute of Ophthalmology, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
4Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
5Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari, Bari, Italy
6Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy
7Department of Ophthalmology and Otolaryngology, University of Bari, Bari, Italy
8Institute of Pediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S., Rome, Italy
9Vasculitis Research Unit and Autoinflammatory Diseases Clinical Unit, Department of Autoimmune Diseases, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

Correspondence should be addressed to Claudia Fabiani; claudia.fabiani@gmail.com and Luca Cantarini; cantariniluca@hotmail.com

Received 22 August 2019; Revised 19 December 2019; Accepted 3 January 2020; Published 17 January 2020

Academic Editor: Calogero Caruso

Copyright © 2020 Claudia Fabiani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess the efficacy of biologic drugs, beyond tumor necrosis factor-α (TNF-α) inhibitors, in the management of noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods. This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results. Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months ($p = 0.002$) and from baseline to the last follow-up visit ($p = 0.002$). Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy ($p = 0.007$). No differences regarding BCVA were observed ($p = 0.67$). Regarding adverse events, only one patient developed pneumonia and septic shock under rituximab treatment. Conclusions. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses.

1. Introduction

Noninfectious scleritis is a severe inflammatory disease of the white outer coating of the eye frequently associated with underlying systemic inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, relapsing polychondritis, and systemic vasculitides [1, 2]. The most aggressive forms of scleritis, such as necrotizing scleritis and posterior scleritis, represent conditions at high risk of serious functional and anatomical sequelae. The most dreaded complication of scleritis is perforation, which can lead to loss of the eye [1]. Moreover, damage to contiguous
inflamed ocular structures such as cornea, uvea, and retina may also occur and leave permanent scarring responsible for irreversible visual impairment. Early diagnosis in these cases is paramount, as aggressive treatment with systemic high-dose glucocorticoids (GCs) in the acute phase and long-term conventional disease-modifying antirheumatic drugs (cDMARDs) on the long term is required [1]. In refractory and most severe cases, several biologics have been employed to control scleral inflammation. Among biologic agents, tumor necrosis factor- (TNF-) α inhibitors have shown to induce a complete and rapid control of scleral inflammation within a few weeks from the start of treatment [3, 4]. Beyond TNF-α inhibition, a prospective randomized double-masked trial by Suhler et al. found that the anti-CD 20 monoclonal antibody rituximab is effective and well tolerated during a 24-week follow-up period [5]. However, only small case series or isolated case reports have been reported on the use of other different biologics [6–11]. In this regard, we report herein our experience on the effectiveness of several different biologic agents, with mechanism of action different from TNF-α inhibitors, in the management of noninfectious recalcitrant scleritis.

2. Patients and Methods

2.1. Study Participants and Screening Methodology. We conducted a retrospective evaluation of patients attending four tertiary ophthalmologic and rheumatologic clinics for the management and treatment of inflammatory ocular and systemic diseases who were affected by noninfectious scleritis and treated with biologic agents with mechanism of action different from TNF-α inhibitors. Patients with scleritis effectively treated with systemic TNF-α inhibitors were not included in this study. Treatment with biologics was established for both active noninfectious refractory scleritis and/or uncontrolled systemic disease associated with scleritis.

The study was approved by the Local Ethic Committee (Prot. N 14951) and adhered to the tenets of the Declaration of Helsinki. A written informed consent was obtained by all study participants or their legal guardians. Patients were screened for latent or active infections before starting the biologic agent with exams including chest radiography, Mantoux or QuantiFERON tests, HBV, HCV, HIV, syphilis, Borrelia burgdorferi serologies, and urine culture.

The following demographic, clinical, and therapeutic data were retrospectively collected: age, sex, class I human leukocyte antigen, age at scleritis onset, disease duration, scleritis relapses,ocular complications, preceding biologic therapy and cDMARDs, preceding local or systemic GCs, and adverse events (AEs). Patients were regularly examined every 3 months and in case of necessity (AEs or disease flare) by either the ophthalmologist or the rheumatologist/internist.

Our study is aimed at evaluating the efficacy of different biologic agents, beyond TNF-α inhibition, in terms of control of scleral inflammation, number of ocular relapses, GC-sparing effect, and visual acuity. Moreover, we recorded the safety profile of therapies and assessed any ocular complication occurring during treatment.

| Table 1: Demographic and clinical features of our cohort of 14 patients. |
|------------------|-----------------|
| **Demographic, laboratory, and clinical data** | **Mean ± SD** |
| Age (years) | 47.29 ± 17.73 |
| Age at scleritis onset (years) | 42.57 ± 18.54 |
| Disease duration (years) | 5.00 ± 3.01 |
| **HLA (N)** | **NHLA** |
| HLA-B51 (4) | |
| HLA-B27 (1) | |
| HLA-B35 (1) | |
| Female/male (N) | 8/6 |
| Eye disease | |
| Anterior diffuse scleritis | 11 (57.89%) |
| Anterior nodular scleritis | 4 (21.05%) |
| Anterior necrotizing scleritis | 1 (5.26%) |
| Posterior scleritis | 3 (15.80%) |
| Concomitant uveitis | 4 (4 AU) |
| Associated keratitis | 3 PUK |
| Associated systemic disease | |
| Rheumatoid arthritis | 7 |
| Granulomatosis with polyangiitis | 2 |
| Microscopic polyangiitis | 1 |
| Psoriatic arthritis | 1 |
| Familial Mediterranean fever | 1 |

AU: anterior uveitis; HLA: human leukocyte antigen; PUK: peripheral ulcerative keratitis; SD: standard deviation.

2.2. Ophthalmologic and Systemic Work-Up. All study participants underwent regular complete ophthalmologic examinations and systemic work-up assessments. Ophthalmologic examination included evaluation of best-corrected visual acuity (BCVA), measurement of intraocular pressure, complete slit lamp examination, and fundus examination. Optical coherence tomography was performed to establish any morphologic macular change at a retinal and choroidal level. Ocular ultrasonography and/or orbit MR scan were performed to confirm the diagnosis of posterior scleritis. Anatomical pattern of scleritis was classified according to the scheme proposed by Watson and Hayreh [12], whereas scleral inflammation was evaluated according to the scleritis grading system proposed by Sen et al. [13], with a score ranging from 0 to 4+. An extensive multidisciplinary work-up was also performed to investigate for a potential underlying systemic disease.

2.3. Statistics. Data were analyzed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, NY, United States). Descriptive statistics was employed to display mean and standard deviation (SD) or median and interquartile range (IQR) as appropriate. Normality was assessed by Shapiro–Wilk test. Repeated ordinal data were computed with Friedman test followed by post hoc Wilcoxon rank sum test. Means were compared by unpaired t-test or Mann–Whitney U test as needed. The threshold for statistical significance was set to \( p < 0.05 \), and all \( p \) values were two sided.
serious adverse event (pneumonia and septic shock)

A signiﬁcantly decreased during the follow-up period (p < 0.0001). More in detail, a signiﬁcant decrease was detected between baseline and 3 months (median ± IQR 2 ± 4 and 0 ± 1, respectively, p = 0.002) and between baseline and the last follow-up visit (median ± IQR 2 ± 4 and 0 ± 1, respectively, p = 0.002), while no signiﬁcant differences emerged between 3 months and the last follow-up visit (p = 0.414). Resolution of scleritis was achieved in 10 out of 19 eyes. In the remaining 9 eyes, scleritis improved in 2 eyes, remained quiescent in 4 eyes, did not improve in 2 eyes, and worsened in 1 eye.

A signiﬁcant decrease in the number of scleritis relapses between the 12 months preceding and following biologic therapy was identiﬁed (p = 0.007). A GC-sparing effect was also observed (mean GCs before treatment was 15.13 ± 9.25 mg/daily of prednisone or equivalent; mean GCs at last follow-up was 5.14 ± 4.63 mg/daily of prednisone or equivalent; p = 0.016).

With regard to AEs, only one patient developed a serious adverse event (pneumonia and septic shock) 1 month after the introduction of rituximab. The following ocular complications developed in 6 eyes: cataract (n = 3), scleral thinning (n = 3), infectious keratitis that required tectonic patch because of impending perforation (n = 1), and macular subatrophy (n = 1). No signiﬁcant differences regarding BCVA values were observed between baseline and the last follow-up visit (median ± IQR 10 ± 3 and 10 ± 1, respectively) (p = 0.67).

3. Results

Nineteen eyes of 14 patients were included in the study. Most patients were from Caucasian ancestry (85.7%) except 2 (1 Afro-American and 1 Hispanic). Female patients represented 57% of the study participants. Demographic data, type of eye involvement, and associated systemic diseases are summarized in Table 1 whereas a detailed description of clinical characteristics and treatment data of the 14 patients enrolled is provided in Tables 2 and 3. Biologic therapy was initiated for active scleritis in 9 out of 14 patients (64.3%) and the remaining 5 because of the associated systemic disease (rheumatoid arthritis in 4 patients and granulomatosis with polyangiitis in one patient). Median ± IQR treatment duration was 13.5 ± 25.50 months, with a minimum of 1 month, a maximum of 56 months, and a range of 55 months.

The scleritis grade signiﬁcantly decreased during the follow-up period (p < 0.0001). More in detail, a signiﬁcant decrease was detected between baseline and 3 months (median ± IQR 2 ± 4 and 0 ± 1, respectively, p = 0.002) and between baseline and the last follow-up visit (median ± IQR 2 ± 4 and 0 ± 1, respectively, p = 0.002), while no signiﬁcant differences emerged between 3 months and the last follow-up visit (p = 0.414). Resolution of scleritis was achieved in 10 out of 19 eyes. In the remaining 9 eyes, scleritis improved in 2 eyes, remained quiescent in 4 eyes, did not improve in 2 eyes, and worsened in 1 eye.

A signiﬁcant decrease in the number of scleritis relapses between the 12 months preceding and following biologic therapy was identiﬁed (p = 0.007). A GC-sparing effect was also observed (mean GCs before treatment was 15.13 ± 9.25 mg/daily of prednisone or equivalent; mean GCs at last follow-up was 5.14 ± 4.63 mg/daily of prednisone or equivalent; p = 0.016).

With regard to AEs, only one patient developed a serious adverse event (pneumonia and septic shock) 1 month after the introduction of rituximab. The following ocular complications developed in 6 eyes: cataract (n = 3), scleral thinning (n = 3), infectious keratitis that required tectonic patch because of impending perforation (n = 1), and macular subatrophy (n = 1). No signiﬁcant differences regarding BCVA values were observed between baseline and the last follow-up visit (median ± IQR 10 ± 3 and 10 ± 1, respectively) (p = 0.67).

4. Discussion

The advent of biologic therapy has revolutionized the management of noninfectious intraocular inﬂammation. However, most of the reported literature is primarily focused in the treatment of uveitis [14], whereas the efﬁcacy and safety of biologics in scleritis have mainly been addressed by single case reports and small case series [6–11, 15].

Based on our ﬁndings, therapy with different biologic agents has resulted in a rapid control of scleral inﬂammation within 3 months from the start of treatment. Similar results were reported in other studies as well. Treatment with the interleukin- (IL-) 1 receptor antagonist anakinra resulted in a rapid improvement within 1 month in a case series of 10 consecutive patients affected by severe and refractory nonnecrotizing scleritis [7]. Silpa-Archa et al. reported the achievement of inﬂammation control with steroid-sparing effect in 50% of their scleritis patients under the IL-6 inhibitor tocilizumab. They also observed a faster response to tocilizumab in scleritis compared to patients with uveitis [10].

In our cohort, alongside the rapid efﬁcacy in controlling scleral inﬂammation, scleritis grade decreased signiﬁcantly also from baseline to the last follow-up visit, which advocates for a prolonged effectiveness over time. Additionally, we also observed a signiﬁcant decrease in the number of scleritis relapses.

| Patient | Age/sex | Anatomical pattern | Laterality | Systemic disease | Preceding biologics and their dose |
|---------|---------|-------------------|------------|-----------------|----------------------------------|
| 1       | 42/M    | Nodular AS        | Bilateral  | GPA             | —                                |
| 2       | 76/M    | Necrotizing AS    | Unilateral | MPA             | —                                |
| 3       | 66/M    | Diffuse AS        | Unilateral | RA              | —                                |
| 4       | 16/F    | Posterior scleritis | Unilateral | Idiopathic     | —                                |
| 5       | 32/F    | Diffuse AS        | Unilateral | GPA             | —                                |
| 6       | 56/F    | Diffuse AS        | Bilateral  | RA              | ADA (40 mg/2 weeks), ABA (125 mg/week), IFX (5 mg/kg/4 weeks) |
| 7       | 46/M    | Diffuse AS        | Unilateral | PsA             | ADA 40 mg/2 weeks, IFX (5 mg/kg/4 weeks) |
| 8       | 18/F    | Posterior scleritis | Unilateral | Idiopathic     | RTX (2 gr/6 months)               |
| 9       | 59/M    | Nodular AS        | Bilateral  | RA              | —                                |
| 10      | 66/M    | Posterior scleritis | Unilateral | FMF             | —                                |
| 11      | 54/F    | Diffuse AS        | Bilateral  | RA              | ADA (40 mg/2 weeks)               |
| 12      | 52/F    | Diffuse AS        | Unilateral | RA              | —                                |
| 13      | 34/F    | Diffuse AS        | Unilateral | RA              | —                                |
| 14      | 45/F    | Diffuse AS        | Bilateral  | RA              | ETN (50 mg/week), ADA (40 mg/2 weeks), TCZ (162 mg/week), RTX (2 gr/6 months) |

ABA: abatacept; ADA: adalimumab; AS: anterior scleritis; F: female; GPA: granulomatosis with polyangiitis; IFX: infliximab; M: male; MPA: microscopic polyangiitis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RTX: rituximab; TCZ: tocilizumab.

3 Mediators of Inflammation

Table 2: Clinical characteristics and past treatments of 14 patients enrolled.
## Table 3: Current treatment and ocular data regarding scleritis grading and number of relapses in our cohort of patients.

| Patient | Ongoing treatment and dosage | Indication | Treatment duration (months) | Scleritis grading before therapy | Scleritis grading at last follow-up | No. of relapses 12 months preceding therapy | No. of relapses after 12 months of therapy | No. of relapses at last follow-up | cDMARDs | GCs§ | AE |
|---------|--------------------------------|------------|-----------------------------|--------------------------------|----------------------------------|---------------------------------------------|--------------------------------------------|----------------------------------|----------|-------|-----|
| 1       | RTX*                           | Scleritis  | 7                           | 2                               | 0                                 | 3                                           | NC                                         | 0                  | MFA      | 10   | —   |
| 2       | RTX 2 gr                       | Scleritis  | 1                           | —                               | —                                 | 3                                           | NC                                         | 0                  | —        | —    | —   |
| 3       | RTX*                           | Scleritis  | 15                          | —                               | 4                                 | 3                                           | 0                                          | —                  | LFN      | 5    | —   |
| 4       | RTX 2 gr/6 months              | Scleritis  | 12                          | 3                               | 4                                 | 3                                           | 0                                          | —                  | —        | —    | —   |
| 5       | RTX 2 gr/6 months              | Systemic   | 30                          | 2                               | 0                                 | 1                                           | 0                                          | —                  | AzA      | —    | —   |
| 6       | TCZ 162 mg/week                | Scleritis  | 3                           | 0                               | 0                                 | 3                                           | NC                                         | 0                  | —        | —    | —   |
| 7       | TCZ 162 mg/week                | Scleritis  | 28                          | 2                               | 0                                 | 4                                           | 1                                          | —                  | 5        | —    | —   |
| 8       | ANA 100 mg/day                 | Scleritis  | 1                           | 4                               | 3                                 | 3                                           | NC                                         | 0                  | —        | 2.5  | —   |
| 9       | ANA 100 mg/day                 | Scleritis  | 3                           | 4                               | 0                                 | 3                                           | NC                                         | 0                  | MTX      | 12.5 | —   |
| 10      | ANA 100 mg/day                 | Scleritis  | 44                          | —                               | —                                 | 1                                           | 0                                          | —                  | —        | —    | —   |
| 11      | ABA 125 mg/week                | Systemic   | 24                          | 4                               | 4                                 | 3                                           | 3                                          | 3                  | —        | —    | —   |
| 12      | ABA 125 mg/week                | Systemic   | 56                          | —                               | —                                 | 1                                           | 0                                          | 0                  | MTX      | —    | —   |
| 13      | ABA 125 mg/week                | Systemic   | 15                          | —                               | —                                 | 2                                           | 0                                          | 1                  | MTX      | —    | —   |
| 14      | TFC 5 mg twice daily           | Systemic   | 6                           | 0                               | 0                                 | 2                                           | 0                                          | 1                  | NC       | —    | 5   |

ABA: abatacept; ANA: anakinra; AE: adverse event; AZA: azathioprine; cDMARDs: conventional disease-modifying antirheumatic drugs; GCs: glucocorticoids; LE: left eye; LFN: leflunomide; MFA: mycophenolic acid; MTX: methotrexate; No.: number; NC: not calculable; RE: right eye; RTX: rituximab; TCZ: tocilizumab; TFC: tofacitinib. *2 loading dose infusions of 1000 mg separated by 2 weeks and 500 mg every 6 months thereafter. †Pneumonia and septic shock. §Daily intake of glucocorticoids (prednisone or equivalent expressed in mg).
Among biologic treatment, B cell-depletion therapy seemed to be another feasible option in achieving a longstanding scleritis remission [5, 11]. Indeed, Suhler et al. found the anti-CD 20 monoclonal antibody rituximab to be effective and well tolerated on a 24-week period in patients affected by refractory scleritis. Interestingly, no notable differences in terms of efficacy and toxicity were found between patients receiving 500 mg and those receiving 1000 mg of rituximab [5]. In a retrospective case series of 15 patients with a mean follow-up of 34 months, rituximab was shown to be effective for recalcitrant noninfectious scleritis and in some cases resulted in a long-term durable drug-free remission. However, the authors stated that aggressive rituximab regimens with higher dosages were required to maintain steroid-free remission [11]. One of our patients (patient 4) treated with rituximab did not show any improvement of scleral inflammation. She was initially diagnosed with an orbital inflammatory disease and was therefore prescribed rituximab based on recent reports of its efficacy in this condition [16, 17]. She is now under investigation to start an anti-TNF-α monoclonal antibody.

In this regard, we could not evaluate any potential statistical difference between various treatment regimens, due to the low number of patients treated with rituximab included in our study.

Concerning to visual function, 14 out of 19 eyes (73.68%) presented with a BCVA ≥ 9 at baseline. Therefore, the lack of significant differences between baseline and the last follow-up visit suggests an ability of biologic therapy to preserve visual acuity over time in scleritis patients.

To the best of our knowledge, we report the first cases of refractory scleritis treated with the recombinant fusion protein abatacept and the Janus kinase inhibitor tofacitinib. More in detail, among the 4 patients (6 eyes) treated with either abatacept or the small molecule tofacitinib, all had an active anterior diffuse scleritis at baseline and all but one achieved resolution of ocular inflammation at the last follow-up visit.

Several biologic agents with a different mechanism of action from anti-TNF-α inhibitors were found to be effective in most of our patients. However, in some cases, the above-mentioned drugs did not show the same efficacy. This is likely to be explained by the heterogeneity of our sample determining distinct pathogenetic backgrounds in accordance to different systemic diseases encountered in our cohort. Therefore, in addition to its anatomical pattern, scleritis treatment should be ideally tailored also by taking into account the associated systemic disorder. In case of idiopathic scleritis, the response to treatment may vary due to the possible activation of different unknown underlying pathogenetic pathways.

However, with the expanding number of biologics available, the prognosis of scleritis, either idiopathic or associated with systemic immune-mediated disorders, may experience a radical change.

To date, we are far from drawing firm conclusions, and our current limited knowledge warrants further studies prospectively designed with larger samples of patients to shed light on this topic. Indeed, our present study comprises several limitations, including its retrospective design, the small sample size, and therapeutic heterogeneity with different biologic agents employed before study entry and within study period.

In conclusion, our results highlight the effectiveness of several biologic agents in the treatment of noninfectious refractory scleritis, showing their potential ability in controlling scleral inflammation and determining a significant reduction in the number of relapses, while preserving visual acuity and displaying an excellent safety profile.

**Data Availability**

The data used to support the findings of this study are available from the corresponding authors upon request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] D. Wakefield, N. Di Girolamo, S. Thurau, G. Wildner, and P. McCluskey, "Scleritis: immunopathogenesis and molecular basis for therapy," *Progress in Retinal and Eye Research*, vol. 35, pp. 44–62, 2013.

[2] E. K. Akpek, J. E. Thorne, F. A. Qazi, D. V. Do, and D. A. Jabs, "Evaluation of patients with scleritis for systemic disease," *Ophthalmology*, vol. 111, no. 3, pp. 501–506, 2004.

[3] A. Ragam, A. M. Kolomeyer, C. Fang, Y. Xu, and D. S. Chu, "Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors," *Ocular Immunology and Inflammation*, vol. 22, no. 6, pp. 469–477, 2014.

[4] P. Doctor, A. Sultan, S. Syed, W. Christen, P. Bhat, and C. S. Foster, "Infliximab for the treatment of refractory scleritis," *The British Journal of Ophthalmology*, vol. 94, no. 5, pp. 579–583, 2010.

[5] E. B. Suhler, L. L. Lim, R. M. Beardsley et al., "Rituximab therapy for refractory scleritis: results of a phase II/III dose-ranging, randomized, clinical trial," *Ophthalmology*, vol. 121, no. 10, pp. 1885–1891, 2014.

[6] C. Botsios, P. Sfriso, P. A. Ostuni, S. Todesco, and L. Punzi, "Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases," *Rheumatology*, vol. 46, no. 6, pp. 1042–1043, 2007.

[7] C. Bottin, A. Fel, N. Butel et al., "Anakinra in the treatment of patients with refractory scleritis: a pilot study," *Ocular Immunology and Inflammation*, vol. 26, no. 6, pp. 915–920, 2015.

[8] J. Tode, R. Zeuner, M. Saeger, J. Roider, and B. Nölle, "Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis," *Acta Ophthalmologica*, vol. 93, no. 8, pp. e683–e684, 2015.

[9] H. Shimizu and H. Nishioka, "Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis," *Scandinavian Journal of Rheumatology*, vol. 46, no. 5, pp. 418–419, 2017.

[10] S. Silpa-Archa, M. Oray, J. M. Preble, and C. S. Foster, "Outcome of tocilizumab treatment in refractory ocular inflammatory diseases," *Acta Ophthalmologica*, vol. 94, no. 6, pp. e400–e406, 2016.
Mediators of Inflammation

[11] J. H. Cao, M. Oray, L. Cocho, and C. S. Foster, "Rituximab in the treatment of refractory noninfectious scleritis," *American Journal of Ophthalmology*, vol. 164, pp. 22–28, 2016.

[12] P. G. Watson and S. S. Hayreh, "Scleritis and episcleritis," *The British Journal of Ophthalmology*, vol. 60, no. 3, pp. 163–191, 1976.

[13] H. N. Sen, A. A. Sangave, D. A. Goldstein et al., "A standardized grading system for scleritis," *Ophthalmology*, vol. 118, no. 4, pp. 768–771, 2011.

[14] A. Trivedi and C. Katelaris, "The use of biologic agents in the management of uveitis," *Internal Medicine Journal*, vol. 49, no. 11, pp. 1352–1363, 2019.

[15] T. S. de Fidelix, L. A. Vieira, D. de Freitas, and V. F. Trevisani, "Biologic therapy for refractory scleritis: a new treatment perspective," *International Ophthalmology*, vol. 35, no. 6, pp. 903–912, 2015.

[16] G. Savino, R. Battendieri, A. Siniscalco et al., "Intraorbital injection of rituximab in idiopathic orbital inflammatory syndrome: case reports," *Rheumatology International*, vol. 35, no. 1, pp. 183–188, 2015.

[17] K. G. Laban, R. Kalmann, R. J. Leguit, and B. de Keizer, "Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease," *EJNMMI Research*, vol. 9, no. 1, p. 69, 2019.